Praxis Precision Q2 net loss widens on higher expenses

Praxis Precision Medicines

06/08/2026 13:12

Overview
US CNS drug developer's Q2 net loss widened yr/yr on higher operating expenses
Company ended Q2 with $1.4 bln in cash and investments, funding runway into 2028

Result Drivers
R&D SPENDING - Higher Q2 research and development expenses driven by increased costs for Solidus platform and personnel, partly offset by lower Cerebrum expenses
ADMINISTRATIVE COSTS - General and administrative expenses rose due to higher professional and personnel-related costs
COMMERCIAL PREPARATIONS - Increased spending on commercial infrastructure and launch readiness for late-stage pipeline programs

Company press release: ID:nGNX1pqzq3

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Loss Per Share
 
$2.87
 
Q2 Net Loss
 
$83.72 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 17 "strong buy" or "buy", 1 "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Praxis Precision Medicines, Inc. is $550.00, about 72.3% above its August 5 closing price of $319.23

Reuters Recommended Reads
Aug 6 - Ireland's GH Research Q2 net loss widens on higher R&D costs
Aug 5 - Vanda Pharmaceuticals Q2 loss widens on lower sales, higher costs
Aug 4 - Harmony Biosciences Q2 WAKIX revenue beats on patient growth

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)